Patents Assigned to Wakunaga Pharmaceutical Co., Ltd.
  • Publication number: 20200147021
    Abstract: Provided is a blood flow improver which is safe and has a mild action. The blood flow improver comprises S-1-propenylcysteine or a salt thereof as an active ingredient.
    Type: Application
    Filed: August 6, 2018
    Publication date: May 14, 2020
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuyasu USHIJIMA, Kayo KUNIMURA, Yukihiro KODERA, Naoaki MORIHARA
  • Publication number: 20200062752
    Abstract: It is intended to provide a novel compound having high antitumor activity and low toxicity to normal cells.
    Type: Application
    Filed: March 23, 2018
    Publication date: February 27, 2020
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Tomonori YAMAGUCHI, Kenji ITOH, Tatsuya HIRANO, Rumiko SHIMABARA, Yohei KAWAKUBO, Masayuki SATO, Junpei YAMASHITA, Akira YAZAKI, Taichi UESHIMA
  • Patent number: 10532984
    Abstract: A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R2 is —NH—R6, where R6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R7, where R7 is hydrogen, a lower alkyl group, or the like; —(CH2)m—R8, where R8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R9aR9b, where R9a and R9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R4 is hydrogen or a carboxyl group-protecting group; and R5 is hydrogen or a hydroxyl group-protecting group.
    Type: Grant
    Filed: June 14, 2017
    Date of Patent: January 14, 2020
    Assignee: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiko Kinoshita, Yasuhiro Kuramoto, Satoshi Inoue, Kouji Nishimura, Tatsuya Hirano, Mai Arai, Asuka Sakurai, Daichi Kazamori, Ayuka Sasaki
  • Publication number: 20190276407
    Abstract: A pyridonecarboxylic acid derivative or a salt thereof is represented by Formula (1), where R1 is hydrogen, a halogen atom, a lower alkyl group, or an amino group; R2 is —NH—R6, where R6 is hydrogen, a lower alkyl group, an amino lower alkyl group, or the like; —O—R7, where R7 is hydrogen, a lower alkyl group, or the like; —(CH2)m—R8, where R8 is an amino group or the like, m is 1, 2, 3 or 4; or a cyclic amino group of Formula (2), where Y represents NH or C—R9aR9b, where R9a and R9b are each independently hydrogen, a lower alkyl group, an amino group, a lower alkyl amino group, or the like; n and p are 1 or 2; R3 is hydrogen, a halogen atom, a lower alkyl group, or the like; R4 is hydrogen or a carboxyl group-protecting group; and R5 is hydrogen or a hydroxyl group-protecting group.
    Type: Application
    Filed: June 14, 2017
    Publication date: September 12, 2019
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Tomohiko KINOSHITA, Yasuhiro KURAMOTO, Satoshi INOUE, Kouji NISHIMURA, Tatsuya HIRANO, Mai ARAI, Asuka SAKURAI, Daichi KAZAMORI, Ayuka SASAKI
  • Patent number: 10363234
    Abstract: Provided is an antihypertensive agent that is safe and has a mild effect. An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: June 10, 2016
    Date of Patent: July 30, 2019
    Assignee: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuyasu Ushijima, Miyuki Takashima, Yukihiro Kodera, Naoaki Morihara
  • Patent number: 10238616
    Abstract: An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: March 26, 2019
    Assignee: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Junichiro Suzuki, Yukihiro Kodera, Kenji Itoh, Toshiaki Matsutomo
  • Publication number: 20180147170
    Abstract: Provided is an antihypertensive agent that is safe and has a mild effect. An antihypertensive agent comprising S-1-propenylcysteine or a salt thereof as an active ingredient.
    Type: Application
    Filed: June 10, 2016
    Publication date: May 31, 2018
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Mitsuyasu USHIJIMA, Miyuki TAKASHIMA, Yukihiro KODERA, Naoaki MORIHARA
  • Publication number: 20170360731
    Abstract: An immunomodulator useful for modulating immune function and maintaining intravital homeostasis is provided. The immunomodulator comprises S-1-propenycysteine or a salt thereof as an active ingredient.
    Type: Application
    Filed: December 4, 2015
    Publication date: December 21, 2017
    Applicant: WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Junichiro SUZUKI, Yukihoro KODERA, Kenji ITOH, Toshiaki MATSUTOMO
  • Patent number: 9079961
    Abstract: An object of the present invention is to provide a probe, primer, primer set and antibody for determining neonatal alloimmune thrombocytopenic purpura or the risk of developing it. According to the present invention, there is provided a probe, primer, primer set and antibody for use in the detection of the thymine residue at position 1297 in the GPIIIa.
    Type: Grant
    Filed: May 26, 2008
    Date of Patent: July 14, 2015
    Assignees: JAPANESE RED CROSS SOCIETY, WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Atsuko Taniue, Hiroyuki Ishii, Shinji Maekawajiri, Nozomi Nagata, Takanori Oka
  • Patent number: 8975411
    Abstract: An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.
    Type: Grant
    Filed: July 15, 2011
    Date of Patent: March 10, 2015
    Assignees: Neugen Pharma Inc., Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Joh-E Ikeda, Noriaki Hirayama, Satoshi Inoue, Kazunori Tanaka, Takuya Kanno
  • Patent number: 8846089
    Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.
    Type: Grant
    Filed: May 30, 2012
    Date of Patent: September 30, 2014
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Yukoh Sakata, Masaharu Higuchi
  • Publication number: 20130190363
    Abstract: An object of the present invention is to provide a pharmaceutical agent useful for treating and preventing neurological disease, having satisfactory solubility and oxidative stress-mediated cell death suppressive activity as well as capable of exhibiting excellent blood-brain barrier permeability. The present invention is directed to an acylaminoimidazole derivative represented by general formula (I) or a salt thereof, and a pharmaceutical and a therapeutic or preventive agent for neurological disease containing the same, as an active ingredient.
    Type: Application
    Filed: July 15, 2011
    Publication date: July 25, 2013
    Applicants: WAKUNAGA PHARMACEUTICAL CO., LTD., NEUGEN PHARMA INC.
    Inventors: Joh-E Ikeda, Noriaki Hirayama, Satoshi Inoue, Kazunori Tanaka, Takuya Kanno
  • Publication number: 20120308656
    Abstract: A method is provided for producing a sugar-coated preparation including a solid composition containing a pharmacologically active ingredient and a sugar coating layer. The method comprises a step of forming the sugar coating layer with a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin. The sugar-coated preparation includes a solid composition containing a pharmacologically active ingredient and a sugar coating layer, wherein the sugar coating layer is made of a sugar coating composition containing one or more sugar-alcohols selected from the group consisting of mannitol and erythritol and a polyvinyl alcohol-based resin.
    Type: Application
    Filed: May 30, 2012
    Publication date: December 6, 2012
    Applicant: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Yukoh Sakata, Masaharu Higuchi
  • Patent number: 8173684
    Abstract: A compound represented by the formula (I): wherein R1 is lower alkyl, cycloalkyl or aromatic hydrocarbon ring, each of which is optionally substituted with one or more substituents; R2 is hydrogen atom, halogen atom, lower alkyl, halo(lower)alkyl or lower alkoxy; and R3 is (1) a group represented by the formula: wherein R4 is lower alkyl, etc.; (2) a group represented by the formula: wherein R5 is lower alkyl, etc.; (3) a group represented by the formula: wherein R6 is lower alkyl, etc.; or (4) a group selected from halogen atom, carboxy, hydroxy and lower alkoxy, or a salt thereof.
    Type: Grant
    Filed: May 2, 2008
    Date of Patent: May 8, 2012
    Assignees: Astellas Pharma Inc., Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Chiyoshi Kasahara, Hitoshi Yamazaki
  • Patent number: 8008028
    Abstract: A panel cell for detecting anti-HNA antibody is disclosed. The panel cell is obtained by introducing a DNA coding for an HNA antigen corresponding to the anti-HNA antibody into a cell so as to enable the expression of the DNA under the condition for use in the detection procedure, wherein the cell for DNA introduction exhibits no detectable reaction with anti-HLA-ABC antibody, anti-HLA-DR antibody, anti-HLA-DQ antibody, anti-HLA-DP antibody, anti-HNA-1 antibody, anti-HNA-2a antibody, anti-HNA-3a antibody, anti-HNA-4 antibody, anti-HNA-5 antibody, and serum from normal subject, in the detection procedure. The panel cell allows accurate and rapid detection of granulocyte antibody.
    Type: Grant
    Filed: March 13, 2007
    Date of Patent: August 30, 2011
    Assignees: Japanese Red Cross Society, Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Kazuta Yasui, Fumiya Hirayama, Rika Furuta, Nobuki Matsuyama, Yoshitaka Kojima, Toru Miyazaki, Hisami Ikeda, Yoshihisa Watanabe
  • Patent number: 7846475
    Abstract: The present invention provides soft capsules comprising a capsule shell having a water activity lower than that of a capsule filling; and a production process of the soft capsules. The present invention makes it possible to prepare soft capsules without lowering the water activity of an active ingredient of a medicament or the like, which activity varies widely, depending on the active ingredient employed, leading to the provision of the soft capsules having original unimpaired properties or stability, and moreover, palatability and texture.
    Type: Grant
    Filed: July 3, 2002
    Date of Patent: December 7, 2010
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Sumihiro Shiraishi, Yoshiyuki Shimokawa, Manabu Udayama
  • Publication number: 20100285147
    Abstract: Provided an acidic liquid preparation containing a herb and/or animal-origin extract at high concentration to suppress time-dependent occurrence of precipitation and/or opacity. A liquid preparation containing a herb-origin extract having pH of 3.0 to 5.5 and containing the herb-origin extract at a concentration of 5 to 50 w/v % (dry weight) to the total amount of the liquid preparation, containing a caramel at a concentration of 0.5 to 20 w/v % to the total amount of the liquid preparation, wherein the caramel has isoelectric point of 2.5 to 4.0 and 1.0 w/v % aqueous solution of the caramel has pH of 4.5 to 6.0. A liquid preparation containing an animal-origin extract having pH of 3.0 to 5.5 and containing the animal-origin extract at concentration of 5 to 50 w/v % (dry weight) to the total amount of the liquid preparation, containing a caramel at concentration of 0.5 to 20 w/v % to the total amount of the liquid preparation, wherein the caramel has isoelectric point of 0.5 to 4.0 and 1.
    Type: Application
    Filed: July 31, 2008
    Publication date: November 11, 2010
    Applicant: WAKUNAGA PHARMACEUTICAL CO. LTD
    Inventors: Soko Motoune, Mizuho Ono, Junichiro Wakamatsu, Shiho Kano, Yoichi Ikeda
  • Patent number: 7713997
    Abstract: The present invention provides an agent which exhibits excellent antibacterial activity, low toxicity, improved bioavailability, and low binding rate to serum proteins. The present invention is directed to a pyridonecarboxylic acid derivative represented by formula (1): or a salt thereof, wherein R1 represents a methyl group, a fluorine atom, or a chlorine atom; R2 represents a hydrogen atom or a lower alkyl group; R3 represents an isopropyl group or a tert-butyl group; R4 represents a methyl group or a halogen atom; and R5 represents a fluorine atom or a chlorine atom. The present invention is also directed to an antibacterial agent and a medicament containing the derivative or the salt thereof as an active ingredient.
    Type: Grant
    Filed: November 17, 2005
    Date of Patent: May 11, 2010
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Akira Yazaki, Yasuhiro Kuramoto, Kenji Itoh, Kazusa Yoshikai, Yuzo Hirao, Yoshihiro Ohshita, Norihiro Hayashi, Hirotaka Amano, Takayuki Amago, Hitomi Takenaka
  • Publication number: 20100063098
    Abstract: A compound represented by the formula (I): wherein R1 is lower alkyl, cycloalkyl or aromatic hydrocarbon ring, each of which is optionally substituted with one or more substituents; R2 is hydrogen atom, halogen atom, lower alkyl, halo(lower)alkyl or lower alkoxy; and R3 is (1) a group represented by the formula: wherein R4 is lower alkyl, etc.; (2) a group represented by the formula: wherein R5 is lower alkyl, etc.; (3) a group represented by the formula: wherein R6 is lower alkyl, etc.; or (4) a group selected from halogen atom, carboxy, hydroxy and lower alkoxy, or a salt thereof.
    Type: Application
    Filed: May 2, 2008
    Publication date: March 11, 2010
    Applicants: Astellas Pharma Inc., WAKUNAGA PHARMACEUTICAL CO., LTD.
    Inventors: Chiyoshi Kasahara, Hitoshi Yamazaki
  • Patent number: 7651706
    Abstract: The present invention relates to a liquid preparation containing crude drug extracts in an amount of 5 to 50 w/v % in terms of a dry extract weight based on the whole amount of the liquid preparation, characterized by containing saccharides in an amount of 5 to 40 w/v % based on the whole amount of the liquid preparation and adjusting a pH to 4.5 to 5.5. This liquid preparation is suppressed in generating precipitate and suspended content with the course of time even if the crude drug extracts are contained in a high concentration and which is stable over a long period of time.
    Type: Grant
    Filed: September 12, 2002
    Date of Patent: January 26, 2010
    Assignee: Wakunaga Pharmaceutical Co., Ltd.
    Inventors: Yoichi Ikeda, Mizuho Ono, Katsunori Nishimura